In the PENELOPE-B trial, the CDK 4/6 inhibitor, Palbociclib, is added to standard endocrine treatment in post-NAC disease in hormone positive BC and in the KATHERINE trial, the combination of Emtansine and Trastuzumab is used as post adjuvant treatment in HER2+ BC. This evidence concerns the gene ERBB2 and breast cancer.